Skip to main content
. 2023 Aug 15;13(13):4512–4525. doi: 10.7150/thno.85946

Figure 5.

Figure 5

Incorporating aspirin in mTCP-μRB scaffolds inhibited osteoclast activity in vivo and in vitro in a dosage-dependent manner. (A-B) Representative TRAP staining images (A) and TRAP+ area quantification (B) in the cranial defect treated with 0/10/20 μg Asp-loaded mTCP-μRB scaffolds at week 2. (n = 3/group) (C-D) Representative TRAP staining images (C) and quantification (D) of OCs on the mTCP-μRB scaffolds treated with varying concentrations of Asp in vitro at day 5. (E) Normalized gene expression of OC markers in vitro at day 5. (n = 4/group). Scale bar in (A, C): 200 μm. *P < 0.05, **P < 0.01, ****P < 0.0001.